FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011447881> ?p ?o ?g. }

• W2011447881 endingPage "394" @default.
• W2011447881 startingPage "388" @default.
• W2011447881 abstract "Patients with metastatic (stage IV) non-small-cell lung cancer usually have a poor prognosis and disease refractory to chemotherapy. Three new agents--taxol, merbarone, and piroxantrone--have shown promising antitumor treatment in vitro and in animals. Taxol is an antimicrotubular agent that interferes with mitosis during cell division. Merbarone, a conjugate of thiobarbituric acid and aniline, is a topoisomerase II inhibitor, which thus inhibits DNA synthesis and tumor growth. Piroxantrone, an anthracenedione derivative, is a DNA intercalating agent that has shown potent antitumor activity in animal studies.Our randomized phase II study was designed to evaluate the efficacy and toxicity of these agents in the treatment of stage IV metastatic non-small-cell lung cancer.Eligible patients (119) were randomly assigned to receive one of the three treatments given every 3 weeks: 250 mg/m2 taxol by a 24-hour intravenous infusion, 1000 mg/m2 merbarone by continuous intravenous infusion through a central catheter daily for 5 days, or 150 mg/m2 piroxantrone by intravenous infusion over 1 hour. Patients had received no chemotherapy. Response and toxicity were evaluated every 3 weeks.Twenty-five patients were randomly assigned to receive taxol, 47 to receive merbarone, and 47 to receive piroxantrone. One of 44 assessable patients (2.3%) treated with piroxantrone had a complete response. Rates for partial response were 20.8% (five of 24 patients) and 5.7% (two of 35) for assessable patients treated with taxol or merbarone, respectively. One-year survival rates were 41.7%, 21.6%, and 22.6%, and median survival times were 24.1, 19.9, and 29.3 weeks for taxol, merbarone, and piroxantrone, respectively. These differences were not statistically significant, but this study was not designed to compare survival. In general, toxicity was manageable. With premedication, no anaphylaxis was observed with taxol. The most common toxic effects were leukopenia with taxol or piroxantrone treatment and thromboembolic complications with merbarone. Death directly related to treatment occurred in 4% (one patient), 11.4% (four), and 5% (two) of the assessable patients receiving taxol, merbarone, and piroxantrone, respectively. Cardiotoxicity and neurotoxicity occurred only occasionally in all three arms.On the basis of the response rate (20.8% partial response) and 1-year survival rate (41.7%), taxol is an active agent for the treatment of metastatic non-small-cell lung cancer. Merbarone and piroxantrone are relatively inactive.Further study of taxol is warranted. In future studies, taxol should be combined with other agents, and granulocyte colony-stimulating factor should be used to ameliorate myelosuppression." @default.
• W2011447881 created "2016-06-24" @default.
• W2011447881 creator A5008786567 @default.
• W2011447881 creator A5039902445 @default.
• W2011447881 creator A5052461112 @default.
• W2011447881 creator A5070509518 @default.
• W2011447881 creator A5074153446 @default.
• W2011447881 creator A5089941984 @default.
• W2011447881 date "1993-03-03" @default.
• W2011447881 modified "2023-10-13" @default.
• W2011447881 title "Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group Results" @default.
• W2011447881 doi "https://doi.org/10.1093/jnci/85.5.388" @default.
• W2011447881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8094467" @default.
• W2011447881 hasPublicationYear "1993" @default.
• W2011447881 type Work @default.
• W2011447881 sameAs 2011447881 @default.
• W2011447881 citedByCount "326" @default.
• W2011447881 countsByYear W20114478812012 @default.
• W2011447881 countsByYear W20114478812013 @default.
• W2011447881 countsByYear W20114478812014 @default.
• W2011447881 countsByYear W20114478812015 @default.
• W2011447881 countsByYear W20114478812016 @default.
• W2011447881 countsByYear W20114478812017 @default.
• W2011447881 countsByYear W20114478812018 @default.
• W2011447881 countsByYear W20114478812019 @default.
• W2011447881 countsByYear W20114478812020 @default.
• W2011447881 countsByYear W20114478812021 @default.
• W2011447881 countsByYear W20114478812022 @default.
• W2011447881 countsByYear W20114478812023 @default.
• W2011447881 crossrefType "journal-article" @default.
• W2011447881 hasAuthorship W2011447881A5008786567 @default.
• W2011447881 hasAuthorship W2011447881A5039902445 @default.
• W2011447881 hasAuthorship W2011447881A5052461112 @default.
• W2011447881 hasAuthorship W2011447881A5070509518 @default.
• W2011447881 hasAuthorship W2011447881A5074153446 @default.
• W2011447881 hasAuthorship W2011447881A5089941984 @default.
• W2011447881 hasConcept C121608353 @default.
• W2011447881 hasConcept C126322002 @default.
• W2011447881 hasConcept C141071460 @default.
• W2011447881 hasConcept C143998085 @default.
• W2011447881 hasConcept C2776256026 @default.
• W2011447881 hasConcept C2776694085 @default.
• W2011447881 hasConcept C29730261 @default.
• W2011447881 hasConcept C31760486 @default.
• W2011447881 hasConcept C71924100 @default.
• W2011447881 hasConcept C90924648 @default.
• W2011447881 hasConcept C98274493 @default.
• W2011447881 hasConceptScore W2011447881C121608353 @default.
• W2011447881 hasConceptScore W2011447881C126322002 @default.
• W2011447881 hasConceptScore W2011447881C141071460 @default.
• W2011447881 hasConceptScore W2011447881C143998085 @default.
• W2011447881 hasConceptScore W2011447881C2776256026 @default.
• W2011447881 hasConceptScore W2011447881C2776694085 @default.
• W2011447881 hasConceptScore W2011447881C29730261 @default.
• W2011447881 hasConceptScore W2011447881C31760486 @default.
• W2011447881 hasConceptScore W2011447881C71924100 @default.
• W2011447881 hasConceptScore W2011447881C90924648 @default.
• W2011447881 hasConceptScore W2011447881C98274493 @default.
• W2011447881 hasIssue "5" @default.
• W2011447881 hasLocation W20114478811 @default.
• W2011447881 hasLocation W20114478812 @default.
• W2011447881 hasOpenAccess W2011447881 @default.
• W2011447881 hasPrimaryLocation W20114478811 @default.
• W2011447881 hasRelatedWork W2003938723 @default.
• W2011447881 hasRelatedWork W2047967234 @default.
• W2011447881 hasRelatedWork W2055244776 @default.
• W2011447881 hasRelatedWork W2100029565 @default.
• W2011447881 hasRelatedWork W2118496982 @default.
• W2011447881 hasRelatedWork W2348529436 @default.
• W2011447881 hasRelatedWork W2413020017 @default.
• W2011447881 hasRelatedWork W2439875401 @default.
• W2011447881 hasRelatedWork W4238867864 @default.
• W2011447881 hasRelatedWork W2525756941 @default.
• W2011447881 hasVolume "85" @default.
• W2011447881 isParatext "false" @default.
• W2011447881 isRetracted "false" @default.
• W2011447881 magId "2011447881" @default.
• W2011447881 workType "article" @default.